Effects of COX-2 Inhibitor in Temporomandibular Joint Acute Inflammation

Abstract

Since it is recognized that cyclo-oxygenase-2 mediates nociception and the sleep-wake cycle as well, and that acute inflammation of the temporomandibular joint (TMJ) results in sleep disturbances, we hypothesized that cyclo-oxygenase-2 inhibitor would restore the sleep pattern in this inflammatory rat model. First, sleep was monitored after the injection of Freund’s adjuvant (FA group) or saline (SHAM group) into the rats’ temporomandibular joint. Second, etoricoxib was co-administered in these groups. The Freund’s adjuvant group showed a reduction in sleep efficiency, in rapid eye movement (REM), and in non-REM sleep, and an increase in sleep and REM sleep latency when compared with the SHAM group, while etoricoxib substantially increased sleep quality in the Freund’s adjuvant group. These parameters returned progressively to those found in the SHAM group. Etoricoxib improved the sleep parameters, suggesting the involvement of the cyclo-oxygenase-2 enzyme in acute inflammation of the TMJ, specifically in REM sleep.

Get full access to this article

View all access options for this article.

References

Chang DJ, Desjardins PJ, Chen E, Polis AB, McAvoy M, Mockoviak SH, et al. (2002). Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial. Clin Ther 24:490–503.

Cicconetti A, Bartoli A, Ripari F, Ripari A (2004). COX-2 selective inhibitors: a literature review of analgesic efficacy and safety in oral-maxillofacial surgery. Oral Surg Oral Med Oral Radiol Endod 97:139–146.

Hayaishi O (1999). Prostaglandin D2 and sleep–a molecular genetic approach. J Sleep Res 8(Suppl 1):60–64.

Hersh EV, Lally ET, Moore PA (2005). Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? Curr Med Res Opin 21:1217–1226.

Khan AA, Brahim JS, Rowan JS, Dionne RA (2002). In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model. Clin Pharmacol Ther 72:44–49.

Lautenbacher S, Kundermann B, Krieg JC (2006). Sleep deprivation and pain perception. Sleep Med Rev 10:357–369.

Martina SD, Vesta KS, Ripley TL (2005). Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 39:854–862.

Matsumura H, Nakajima T, Osaka T, Satoh S, Kawase K, Kubo E, et al. (1994). Prostaglandin D2-sensitive, sleep-promoting zone defined in the ventral surface of rostral basal forebrain. Proc Natl Acad Sci USA 91:11998–12002.

Moore PA, Hersh EV (2001). Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc 132:451–456; comment 132:1502–1504.

10.

O’Banion MK (1999). Cyclooxygenase-2: molecular biology, pharmacology and neurobiology. Crit Rev Neurobiol 13:45–82.

11.

Ram A, Pandey HP, Matsumura H, Kasahara-Orita K, Nakajima T, Takahata R, et al. (1997). CSF levels of prostaglandin, especially the level of prostaglandin D2, are correlated with increasing propensity towards sleep in rats. Brain Res 751:81–89.

12.

Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. (2001). Interleukin-1beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410:471–475.

13.

Schütz TC, Andersen ML, Tufik S (2003). Sleep alterations in an experimental orofacial pain model in rats. Brain Res 993:164–171.

14.

Schütz TCB, Andersen ML, Tufik S (2004). Influence of temporomandibular joint pain on sleep patterns: role of nitric oxide. J Dent Res 83:693–697.

15.

Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. (1998). Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591–1602.

16.

Simon AM, Manigrasso MB, O’Connor JP (2002). Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17:963–976.

17.

Terao A, Matsumura H, Yoneda H, Saito M (1998). Enhancement of slow-wave sleep by tumor necrosis factor-[alpha] is mediated by cyclooxygenase-2 in rats. Neuroreport 9:3791–3796.

18.

Timo-Iaria C, Negrão N, Schmidek WR, Hoshino K, Lobato de Menezes CE, Leme da Rocha T (1970). Phases and states of sleep in the rat. Physiol Behav 5:1057–1062.

19.

Yoshida H, Kubota T, Krueger JM (2003). A cyclooxygenase-2 inhibitor attenuates spontaneous and TNF-alpha-induced non-rapid eye movement sleep in rabbits. Am J Physiol Regul Integr Comp Physiol 285:R99–R109.

20.

Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109–110.